About
Invivoscribe® is a global leader dedicated to Improving Lives with Precision Diagnostics®, advancing the quality of healthcare by providing innovative products and clinical services for oncology. Our Streamlined CDx® (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. With products manufactured in our state-of-the-art cGMP facility, we provide a comprehensive range of platform agnostic assays, reagents, controls and software for clonal gene rearrangements, translocations, gene mutation testing, and measurable residual disease (MRD). Invivoscribe’s products consistently surpass industry and regulatory standards and play a crucial role in identifying, stratifying and monitoring hematologic cancers, enabling scientific advancements and empowering clinicians to make informed treatment decisions. Our subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM®), offers extensive clinical diagnostic and biopharma services for the detection and monitoring of myelo- and lymphoproliferative disorders. The LabPMM network performs globally standardized flow cytometry and molecular testing services for... Read More
Focus
Office
Lease
Markets
FAQs
Invivoscribe has financed 1 deal.
Invivoscribe's most recent deal was on October 09, 2025.
Member since: October 2025
Deals
Transaction Type
Asset Type
State
Sort By
LEASED
Jeffrey Edward Miller Of Invivoscribe Renews 52477 Square Foot Office Lease In San Diego
10222 Barnes Canyon Road, San Diego, CA
CACRE
Oct 9, 2025